GOBIOM's Biomarker Database for Enabling Precision Medicine

Drug resistance and inadequate response to commonly administered drugs across different therapeutic indications poses a major challenge to clinicians and researchers. This leads to unnecessary heath care costs and is incurring additional research expenditure. Despite marked improvement in new...

Read More

Using Legacy and Current Data to Accelerate Drug Development

A thought-leadership article from Dr. Kavita Lamror, Director - Value Evidence Services, Excelra

“Information is the oil of the 21st century, and analytics is the combustion engine.” – Peter Sondergaard

Randomized controlled trials (RCTs) are the gold standard of evidence for establishing the...

Read More

Data curation for Model Based Meta Analysis (MBMA) - An Integral Part of MID3

Model informed drug discovery and development (MID3) is a paradigm of data analytics in drug development which facilitates the development and application of various quantitative approaches like exposure-response, biological, and statistical models to characterize pre-clinical and clinical data....

Read More

Drug Target Dossier: Target Intelligence for Data Driven Drug Discovery

Introduction to drug target biology and its role in drug discovery

Drug discovery and development is a long, expensive and risky process. On average it takes roughly 12 years and around $2.6 billion to develop a new drug (1). The Food and Drug Administration (FDA) of United States, considered as...

Read More

GOSTAR: The largest online medicinal chemistry intelligence database

In medicinal chemistry, the relationship between molecular structure of a compound and its biological activity is referred to as Structure Activity Relationship (SAR). Medicinal chemists modify biomedical molecules by inserting new chemical groups into the compound and test those modifications...

Read More

Coronavirus Clinical Trials Landscape - Analysis Using Excelra’s COVID-19 Biomarker Database

The ongoing COVID-19 pandemic is continuing to spread rapidly across the globe. As of 30th June 2020, the World Health Organization (WHO) has reported over 10 million cases and half a million deaths across 188 countries. Current clinical research is focused on accelerating the development of...

Read More

Excelra's COVID-19 Biomarker Database-Overview of COVID-19 Research

COVID-19, a pandemic caused by the novel SARS-CoV-2 virus, has rapidly spread across the world in an unprecedented and devastating manner. Currently there are over 5 million confirmed cases and over 360 K deaths as reported by the World Health Organization. Furthermore, there are currently no...

Read More

Ruxolitinib - A Promising Drug Repurposing Candidate for COVID-19

Immune overreaction to a viral infection can lead to a Cytokine storm. It may also result in serious complications such as pneumonia and acute respiratory distress syndrome (ARDS). Ruxolitinib blocks cytokine mediated response by inhibiting the activation of JAK1 and JAK2, a critical...

Read More

Target Dossier

Target identification is an essential first step toward the discovery and development of any new therapeutic. Consequently, successful pharma organizations perform due diligence around a target of interest before embarking on the long, time-consuming, expensive and high-risk endeavor of drug...

Read More

Inhibition of SARS-CoV-2 Infection by Soluble Human ACE2

Reports suggest that SARS-CoV-2 virus has the ability to directly infect human blood vessel and kidney organoids. The use of clinical-grade recombinant human ACE2 (rhACE2) can reduce SARS-CoV-2 infection in cells and multiple human organoid models. Furthermore, the same study has also suggested...

Read More